Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2020.11.057
Abstract: COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class… read more here.
Keywords: challenges monoclonal; antibody therapies; learning past; failures challenges ... See more keywords